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Abstract 
Van Ree, Jan M., Ron Hijman, Jellemer Jolles and David De Wied: Vasopressin and related 
peptides: Animal and human studies. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1985, 9 
G/6): 551-559. 
In animals, vasopressin and related peptides are present in specific neuronal pathways in 
the brain and modulate brain processes. It has been suggested that in particular memory 
processes, including consolidation and retrieval , short and long term memories are faci- 
litated by vasopressin. Evidence has been presented that endogenous vasopressin is involved 
in these processes. But also other effects of these peptides e.g. an attenuation of acqui- 
sition of heroin self-administration have been reported. Vasopressin and related peptides 
have been administered to humans in a number of studies including volunteers and various 
patient populations with and without complaints about memory. Beneficial effects on several 
aspects of memory, learning, attention and concentration have been found, but not in all 
studies. Patients with severe deficits seem to benefit less from the peptide treatment. 
This may be related to the amount of brain damage. Beneficial effects of vasopressin treat- 
ment have been reported in schizophrenics and heroin addicts. In addition effects on social 
behavior, energy and mood of certain patients have been noted. The target patient popula- 
tion for vasopressin neuropeptide is thus not yet well defined. With respect to cognitive 
disorders, sophisticated neuropsychological test procedures, including information- 
processing tasks, may contribute to define such a patient population. These tasks may also 
be applied for treatment evaluation. It should however be kept in mind that other interest- 
ing influences of vasopressin e.g. on social behavior, mood and addictive behavior, may 
also appear of clinical significance. 
information in this respect. 
Future studies in humans may yield more detailed 
Desglycinamide (Arg )-vasopressin or the recently discovered 
potent fragments of vasopressin may be recommended for these studies, because these pep- 
tides are practically devoid of the peripheral "side" effects on water ho 
blood pressure accompanying treatment with vasopressin or desamino-(D-Arg 
tp 
eostasis and 
)vasopressin 
(DDAVP). 
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Introduction 
The hormone vasopressin is synthesized in nerve cell bodies in hypothalamic nuclei 
(nucleus paraventricularis and nucleus supraopticus) and transported via the axons of these 
nerves to the posterior pituitary , where the hormone is stored. Specific stimuli evoked by 
regulatory mechanisms in the body, including the brain, can lead to increased activity 
along the axons, resulting in secretion of vasopressin into the blood stream. Through this 
transport medium, vasopressin reaches its peripheral and possibly its central target sites, 
where it exerts specific effects (e.g. antidiuretic, blood pressure increasing and be- 
havioral effects). 
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Vasopressin is also present in distinct neuronal pathways in the brain (Buijs et al., 
1983). The cell bodies of these neurons in the rat are located in the nucleus suprachias- 
maticus, the nucleus paraventricularis, the bed nucleus of the stria terminalis and others. 
These neurons terminate widespread in the brain; terminals are present e.g. in areas of 
the limbic system, hypothalamus, brain stem and spinal cord. Vasopressin can be released 
from these terminals, and acts as neurotransmitter or neurohormone. The anatomical data 
support the initial effects of vasopressin, which were originally evidenced from be- 
havioral effects of this hormone (De Wied, 1965). 
A lot of evidence is available to date, originating e.g. from behavioral, biochemical, 
and electrophysiological experiments in various animal species (for references see Van Ree 
et al., 1978; Van Wimersma Greldanus et al., 1983, Versteeg, 1983), Indicating that vaso- 
pressin and related neuropeptides affect and modulate brain processes. Although it is im- 
possible to place all these effects into one conception concerning the mode of vasopressin 
action, the attempt to label some of the behavioral effects as an action on learning and 
memory processes has stimulated both animal and human investigations. However, it should 
be kept in mind that the concepts of learning and memory originating from animal and human 
studies are not identical and exchangeable and neither are the various other concepts from 
different disciplines in this respect. This hampers the discussion about this matter. Never- 
theless, this survey endeavours to summarize the effects of vasopressin and related pep- 
tides in animals and humans, focussing on learning and memory processes in particular. 
Synopsis of animal studies 
Arguments in favor of an influence of vasopressin neuropeptides on memory processes 
in rats stem from observations on aversively motivated behavior in particular (for referen- 
ces see Van Ree et al., 1978; Van Wimersma Greidanus et al., 1983; De Wied, 1984). These 
peptides induce a long lasting resistance to extinction of one and two way active avoidance 
behavior, that persists beyond the actual presence of the peptide in the body. The time of 
administration of vasopressin is critically related to task, in that the peptide is es- 
pecially active when administered in the period of some hours before to some hours after 
the behavioral procedure (Bohus et al., 1972). Memory processes involve consolidation and 
retrieval of acquired information. These aspects of memory have been experimentally defined 
using the passive avoidance behavioral test procedure, a simple "step through" apparatus, 
which consists of a dark box to which an illuminated platform is attached. The dark en- 
vironment is preferred by the rat over the platform. The learning trial consists of an 
unpleasant experience in the dark box (electric footshocks of short duration). Rats are 
tested for retention e.g. 24 h after the learning trial. Consolidation of the information 
takes place within a few hours after the learning trial, while retrieval of information is 
needed during the retention test. Vasopressin neuropeptides facilitate retrieval when ad- 
ministered both after the learning and before the retention trial, suggesting that conso- 
lidation as well as retrieval processes are stimulated by these peptides. Although not all 
investigators found similar effects , recent experiments indicate that this may be due to 
the conditions of the experimental procedure. Acquisition of avoidance behavior is improved 
by vasopressin neuropeptides, but only when the rate of acquisition is low, suggesting 
that under certain conditions learning is affected by these peptides. 
Prevention and reversal of retrograde amnesia by vasopressin neuropeptides also favors 
the memory hypothesis. The passive avoidance behavioral test has been employed and amnesia 
was induced by C02-inhalation. electro-convulsive shock or pentylenetetrazol, but also 
puromycin-induced retrograde amnesia for a maze-learning task in mice has been studied to 
explore the effects of vasopressin neuropeptides. Besides, retrograde amnesia can be ln- 
duced by disrupting circadian organization of rats by changing the day-night cycle, re- 
sulting in an attenuated retrieval of recently acquired information (Fekete et al., 1985). 
This behavioral deficit can be restored by vasopressin neuropeptides. The amnesia studies 
generally point to an effect of these peptides on retrieval processes. 
The influence of vasopressin neuropeptides is not restricted to aversively motivated be- 
havior. Peptide effects have been reported on food and sexually motivated behavior. Bow- 
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ever, interpretation of these observations within the scope of the memory hypothesis has 
been questioned. Recently, we have studied the vasopressin action using the hole board 
food search task as developed by Oades, in which hungry rats can search for 4 food pellets 
consistently placed in 4 out of 16 holes (Oades and Isaacson, 1978). The data allow to 
distinguish between learning, working and reference memories and the strategy of the rat 
to obtain the food pellets. A vasopressin neuropeptide (DGAVP) facilitated learning, 
working (comparable to short term) and reference (comparable to long term) memories, but 
did not affect the strategy of the rats (Gaffori et al., in preparation). Vasopressin may 
have in addition a special effect on certain rewarded behaviors. Vasopressin neuropeptides 
reduce acquisition of heroin self-administration in rats and the electrical selfstimula- 
tion elicited from the lateral hypothala~s or the ventral tegmental area. Moreover, vaso- 
pressin treated rats were slower in reaching the learning criteria using a continuously 
reinforced schedule. However, although the reviewed animal data certainly are consistent 
with the memory hypothesis, other explanations for the action of vasopressin are possible 
as well and have indeed been suggested, like an effect on arousal mediated processes 
(Messing and Sparber, 1984; Sahgal, 1984). 
Vasopressin in the body has been implicated in the mechanisms underlying memory processes 
as tested with the mentioned behavioral procedures. Removal of the posterior pituitary re- 
sults in facilitated extinction of active avoidance behavior, which behavioral deficit can 
be corrected by treatment with vasopressin. In addition a homozygous variant of the Brattle- 
boro strain, lacking the ability to synthesize vasopressin , shows deficits in the active 
and passive avoidance behaviors , which are restored by treatment with vasopressin neuropep- 
tides. Similar findings have recently been observed in the hole board food search task 
(Gaffori et al., unpublished data). Temporary bio-inactivation of vasopressin by injecting 
vasopressin antiserum into the brain ventricle attenuates both consolidation and retrieval 
as assessed with the passive avoidance behavioral test. Intravenous administration of the 
antiserum is not effective in this respect , suggesting that vasopressin in the brain rather 
than in the periphery is important for these effects. This notion is supported by the 
findings showing that the dosage of the peptides needed to elicit the behavioral effects 
is much lower after central than after peripheral administration and that central admini- 
stration of vasopressin antagonists, which does not interfere with the peripheral effects 
of vasopressin, effectively antagonized the behavioral effects of vasopressin neuropeptides 
injected either centrally or peripherally (De Wied et al., 1984). 
Concerning the site of vasopressin action in the brain with respect to memory processes, 
lesion studies point to the importance of certain limbic areas including the septal region 
and the hippocampus. Microinjection of picogram amounts of vasopressin into these struc- 
tures and the dorsal raphe nucleus mimics the effect of peripherally administered vaso- 
pressin on consolidation, while local injection of vasopressin-antiserum induces an oppo- 
site effect. Destruction of the ceruleo-telencephalic noradrenaline system with B-hydroxy- 
dopamine prevents the facilitatory effect of vasopressin on consolidation, but not on re- 
trieval processes. In addition biochemical studies have shown that vasopressin modulates 
monoaminergic neuotransmission. Thus, vasopressin may exert its memory effects via an inter- 
action with catecholamine transmission and the lesion studies indicate that the vasopressin 
memory effects are absent when certain brain structures are damaged. 
Besides behavioral effects, vasopressin (AVP) has antidiuretic and blood pressure in- 
creasing effects. Peptides have begn synthesized in order to dissociate these effects from 
each other. DDAVP (desamino-(D-Arg )-vasopressin) induces antidiuretic activity, hardly 
changes the blood pressure, and facilitates memory pgocesses, albeit with a somewhat lower 
potency than vasopressin. DGAVP (desglycinamide-(Arg )-vasopressin) is practically devoid 
of the antidiuretic and blood pressure increasing effect of vasopressin, but is nearly as 
potent as vasopressin in facilitating memory processes. This dissociation is even more 
pronounced in the recently discoXered6peptides, probably gengrated by brain egxymes in 
vivo6from vasopressin e.a. [pClu ,Cyt XVP-(4-9). CpGlu ,Cyt IAVP-(4-81, [Cyt IAVP-(5-g), 
[Cyt 1 AVP-(4-8) (Burbach et al., 1983). These peptides potently mimic the effects of vaso- 
pressin on memory consolidation and retrieval and on experimentally induced amnesia. Some 
evidence is available that these various peptides may selectively facilitate consolidation 
and retrieval processes (Gaffori et al., submitted). 
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Human studies 
Vasopressin and related peptides have been applied to humans in many studies, involving 
volunteers and patients with various disorders including memory disturbances. A summary of 
these studies is presented in Table 1 (for references and details see Jolles, 1983, 1985; 
Legros and Lancranjan, 1984). The studies are quite different in a number of aspects, which 
will briefly be discussed. 
Table 1 
Human studies with vasopressin-related peptides 
NUMBER OF STUDIES POSITIVE TREATMENT NUMBER OF SUBJECTS 
EFFECT TREATED WITH 
VASOPRESSIN 
PATIENTS 
Brain trauma 
Alcoholics 
Elderly/dementia 
Diabetes insipidus 
Children with 
learning/attention disorders 
Depression 
Psychosis 
Addiction 
14 8 103 
11 4 48 
13 7 135 
6 6 58 
6 4 62 
6 5 22 
3 3 112 
3 3 24 
Others 4 2 6 
Total 66 42 570 
VOLUNTEERS 15 13 319 
References: Eisenberg et al., 1984; Fehm- Wolfsdorf et al., 1983; Fraenkel et al., 1983; 
Jensen, 1980; Legros et al., 1983; Lerer et al., 1983; Posmurova et al., 1983; Reichert 
and Blass, 1982; personal communications of Beckwitz, Eisenberg, Hijman, Jolles, Laczi, 
Fehm-Wolfsdorf and Wit; for other references see Jolles, 1983; 1985; Legros and 
Lancranjan, 1984; 
Type of patients 
Because patients suffering from a post-traumatic amnesia, chronic alcoholism and dementia 
(senile dementia, multi-infarct dementia, dementia in Parkinsonism patients) frequently 
complain about memory problems, these patients have been included in most of the human 
studies focussing on memory effects of vasopressin. In addition, elderly people have been 
studied, since a decrease of neurophysin blood levels beyond the age of 50 has been found. 
When vasopressin has a physiological role in modulating learning and memory processes in 
humans, untreated patients suffering from diabetes insipidus may have problems with their 
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learning and memory abilities and could benefit from treatment with vasopressin neuropep- 
tides. Indeed, diabetes insipidus patients scored lower on certain tasks aimed to measure 
attention and short and long term memory, but this was observed only in patients with the 
congenital variant of this disease and not in patients with acquired diabetes insipidus 
(Laczi et al., in preparation). Some studies with children with learning disorders have 
been carried out. Vasopressin neuropeptides have also been applied to psychiatric patients, 
included patients suffering from schizophrenic psychosis and depression, and heroin 
addicts. 
It is hardly conceivable that in all these categories of patients the memory disturbances, 
if present, are similar. Indeed, psychological testing of patients suffering from e.g. 
posttraumatic amnesia and senile dementia have revealed that marked differences are present 
between these groups of patients, but also within one category (Jolles, 1983, 1985). More- 
over, memory complaints not only accompany different types of diseases, but the brain pro- 
cesses underlying these complaints may be quite different. A memory disorder may be due to 
disturbances in memory processes or secondary to other disorders, like a decrease of the 
rate of information processing, decreased attention, or a disorder in the behavioral orga- 
nization or planning. This complicates the studies of vasopressin in humans, since the 
variation between subjects may mask the treatment effects. Thus, it may be advised to se- 
lect for future studies patients with a certain homogenity-with respect to the disorders 
underlying their memory complaints as revealed from sophisticated psychological testing, 
rather than applying the diagnostic classification used sofar. In addition, the severity 
of the symptoms and the degree of brain damage may be important aspects, as will be dis- 
cussed later. 
Psychological tests 
Various psychometric tests have been used to gather information about the memory dis- 
turbances of the patients and to evaluate treatment effects. Since the tests are generally 
applied several times to the same person, the availability of parallel versions seems a 
condition sine qua non, in particular when another than a-placebo-parallel design is fol- 
lowed. This requirement has not been met in all studies. The use of quite different tests 
hampers the comparison of the outcome of the various studies. Most of the applied tests 
measure performance rather than the disturbed aspect of cognitive dysfunctions. Recently, 
test procedures based on information processing models (e.g. the Sternberg Memory Compari- 
son task) have been applied (Nebes et al., 1984; among others). This test allows to dis- 
criminate between effects on the speed of perceptual and motor processes and those on 
memory comparison. A combination of the psychometric, the information processing, and the 
behavioral neurology approach may be fruitful in assessment of cognitive disorders and to 
evaluate treatment effects (Jolles, 1985). 
Another problem arises from the human studies with vasopressin neuropeptides; the sub- 
jective versus the objective effects of treatment. Patients sometimes judged that vaso- 
pressin treatment led to beneficial effects with respect to memory complaints, but the 
outcome of the psychological test procedures did not support these subjective feelings. 
This may be related to the fact that some patients incorrectly label their complaints as 
memory disturbances. It may also be that the applied test procedures are not dealing with 
the complaints of the patients or that the effects of vasopressin are not strong enough to 
produce significant changes in the psychological tests. 
Treatment variables 
The various aspects related to the treatment markedly differ among the studies. The de- 
sign of the studies was open or blind, cross-over or placebo-parallel. The peptides were 
administered intranasally (most frequently used route), orally or intramuscularly once or 
three times a day for 1 to 14 days. For a more general medical use of these peptides, of 
particular interest is the probably oral effectiveness of the peptides. However, only DGAVP 
has been administered via the oral route in two studies with brain trauma patients and in 
one with children (Jolles et al., Wit et al., unpublished data); in addition the peptide 
was sublingually administered to heroin addicts (Fraenkel et al., 1983). That these pep- 
tides may be effective via the oral route is supported by animal data showing that this 
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administration leads to similar effects as subcutaneous treatment (Van Ree, 1982). Besides 
pitressin in the earliers studies with psychotic patients, 4 different vasopressin con- 
geners have been used i.c. AVP, LVP, DDAVP and DGAVP. The peptides AVP and LVP induce 
cardiovascular changes and an antidiuretic action, while DDAVP elicits an antidiuretic 
effect. These effects hamper the "double-blind" character of studies and may interfere 
with the expected effects on brain function. The peptides DGAVP seems to be devoid of these 
peripheral side effects (Laczi et al., 1983) and may therefore be recommended for human 
studies. Although beneficial effects have been reported following a single administration, 
which parallels the effects observed in animal experiments , others have found that the 
improvement started after 4 - 5 days. Long term effects of the peptides have been des- 
cribed. This questions the use of a cross-over design without wash-out period. 
Vasopressin effects in humans 
It seems quite difficult to define a common denomination of the effects of vasopressin 
treatment as reported in the various studies. Beforehand, it should be mentioned that there 
are a number of studies showing no treatment effects of vasopressin. This may be related 
to the variables discussed in the preceding section e.c. the type of patients, the applied 
psychopharmacological tests and the treatment variables. It is worthwhile to mention that 
treatment effects have been observed in 13 out of the 15 studies with volunteers. These 
effects have been described as facilitation of learning, memory , attention and concentra- 
tion (Table 2 ). In most of the categories of patients beneficial effects on memory func- 
tions, particularly retrieval processes, have been reported, although not in all studies. 
In the schizophrenic patients and addicts , memory functions were not evaluated. Concerning 
the vasopressin-induced enhancement of memory processes, different underlying mechanisms 
have been proposed. In general, two actions can be distinguished: a diffuse non-specific 
activating action and a specific action on certain aspects of memory and related processes. 
However, both actions may be present as is suggested by the results of a recent study by 
Nebes et al. (1984), showing that the slope as well as the interception in a memory com- 
parison task are changed by DDAVP treatment, indicating specific memory and "non-specific" 
effects. These authors conclude that both short term and long term memories, but not seman- 
tic memory is improved by DDAVP to the same degree in young and old volunteers. That short 
term and long term memory may be affected is supported by the data of a series of studies 
by Laczi and coworkers (1983 and unpublished data). A number of investigators have sug- 
gested that vasopressin neuropeptides shorten the reaction time of the patients, due to a 
non-specific action on the rate of information processing resulting in an increased effi- 
ciency in the organization of memory. Others have proposed that the facilitation of memory 
is due to an enhanced attention and concentration of the patients. More extensive and de- 
tailed studies are needed before definite conclusions can be made regarding the underlying 
mechanism of vasopressin action in particular with respect to memory functions. 
A number of studies have shown that attention and concentration of patients and volun- 
teers are improved by vasopressin treatment. Improvement of learning has been observed in 
various patients and volunteers. Social behavior of some patients suffering from post- 
traumatic amnesia, dementia and schizophrenia increased by vasopressin treatment. Schizo- 
phrenic patients improved clinically with respect to negative symptoms and the factor an- 
ergia (emotional withdrawal, motor retardation, blunted or inappropriate affect) These 
negative symptoms are, generally , rather resistant to neuroleptic treatment. An increase 
in energy, activity and mood has been reported in schizophrenics. Positive effects on mood 
and energy have also been reported in patients with primary affective disorders and in 
demented and brain trauma patients, in addition to an enhancement of cognitive functions. 
A facilitation of the methadone detoxification and a decreased intake of heroin and cocaine 
have been reported in heroin addicts treated with vasopressin (Fraenkel et al., 1983). 
Summarizing, vasopressin may stimulate processes related to learning, memory, attention 
and concentration in patients and volunteers; the peptide may beneficially affect post- 
traumatic amnesia, negative symptoms of schizophrenia and addictive behavior of heroin 
dependent subjects, elevate mood and energy in various patients and increase social be- 
havior in certain patients. However, it should be stressed that these effects have not 
consistently been observed in all studies and that the clinical significance of the im- 
provements have been questioned. Moreover, not all beneficial effects are based on appro- 
priate and objective testing. 
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Table 2 
Reported beneficial effects of vasopressln neuropeptides 
ATTENTION SOCIAL MOOD 
LEARNING MEMORY CONCENTRATION BEHAVIOR ENERGY REMARKS 
PATIENTS 
Brain trauma + f + + 
Alcoholics + 
Elderly/dementia + 
Diabetes insipidus 
Depression 
Schizophrenia 
Children with learning/ 
+ 
attention disorders + + 
Addiction 
Others + 
VOLUNTEERS + + c 
f + 
+ 
+ 
+ + 
light > severe 
especial rate of 
retrieval/information 
processing 
mild > severe 
mild > severe 
moderate > severe 
improvement of anergia 
and negative symptom5 
decreased intake heroin 
and cocaine 
In general it has been reported that patients with severe deficits respond less favour- 
able to vasopressin than patients with mild symptomatology. This has been observed in 
patients suffering from brain trauma , chronic alcoholism, dementia and affective disorders 
(Table 2). Thus, patient5 with more serious head injuries, patients suffering from 
Korsakoff's syndrome or Alzheimer's disease or severely depressed patients hardly res- 
ponded to vasopressin treatment. This may be related to the severity of the symptom5 or to 
the degree of brain damage. This latter seems reasonable when taken into consideration 
that in animals vasopressin effects on memory processes can hardly been evoked after speci- 
fic brain lesions. Thus, a lack of effect of vasopressfn may be due to lesions in the brain 
areas on which the peptide can be expected to act. Possibly, vasopressin may be particular- 
ly effective in patients with low levels of endogenous peptide. In that case treatment 
with vasopressin can be regarded as a substitution therapy, Decreased levels of neurophysin 
(the vasopressin transport protein) have been found in the blood of men beyond the age of 
50. Vasopressin levels in cerebrospinal fluid (CSF) were not changed with age and in 
patients with multi-infarct amnesia or with Alzheimer's disease (see Legros and Lancranjan, 
1984). A decreased CSF level of vasopressin has been reported in depressed patients as 
compared to control subjects and manic patients , while high levels were found in amnesic 
patients as compared to non-smnesic patients. Although a slight decrease of vasopressin 
levels in certain brain areas has been found in patient5 with Alxheimer's disease, the 
levels did not significantly differ from those of controls matched for age. The size of 
vasopressin cell profile5 in the nucleus supraopticus and the nucleus paraventricularis of 
post-mortem brain showed little change with age, and was not altered in patients with 
Alzheimer's disease; the highest value was found in the age group of 80 - 100 years (Swaab 
et al., 1985). Interestingly, in the suprachiasmatic nucleus a marked decrease in the num- 
ber of vasopressin cells was observed in 80 - 100 years old patients, and this decrease 
was even more pronounced in patients with Alzheimer's disease. This suggests that distur- 
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bances in vasopressin systems in senescence and in Alzheimer's disease are not general but 
restricted to certain specific pathways. The data yet available about vasopressin levels 
in CSF and brain are however not sufficient to draw conclusions with respect to the rela- 
tion between these levels and the effectiveness of vasopressin. 
An important aspect is the clinical significance of the vasopressin effects in humans. 
Most studies in volunteers have revealed effects of peptide treatment on processes such as 
learning, memory, attention and concentration, but the studies in patients have shown less 
consistent results. This may be related to the type of patients and the degree of brain 
damage, as discussed before. Since patients with mild deficits responded particularly to 
peptide treatment, vasopressin neuropeptides may be recommended for patients with light 
brain trauma (e.g. concussion), elderly people with mild senescent forgetfulness, patients 
with very early dementia and depressed patients with mild to moderate symptomatology. In 
addition, beneficial effects of vasopressin have been reported in schizophrenia, especially 
on the neuroleptic-resistant negative symptomatology, in heroin addicts and in children 
with learning and attention disorders. These findings need further exploration, before 
these patients can be regarded as a target population for vasopressin neuropeptides. Also 
the reported beneficial influence on social behavior , mood and energy is worthwhile to 
study in more detail. 
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